"description","label","id","uuid:ID","name","text","instanceType"
"Main objective","","Objective_1","ed7a318e-dbef-40bf-a5f8-b67dafe9022b","OBJ1","To determine if there is a statistically significant relationship (overall Type 1 erroralpha=0.05) between the change in both the ADAS-Cog (11) and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg]).","Objective"
"Safety","","Objective_2","4c7ed8e4-09a0-4c0c-a6f2-deab824a9e99","OBJ2","To document the safety profile of the xanomeline TTS.","Objective"
"Behaviour","","Objective_3","43cd5f93-08fa-4c69-a631-f73ef5f7975d","OBJ3","To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these
areas.","Objective"
